PTGS2 and myocardial infarction: Since 2004, when two COX-2-selective inhibitors, rofecoxib, and valdecoxib, were removed from the market due to an elevated risk of cardiovascular events, including myocardial infarction, celecoxib, as well as other selective and nonselective Non-steroidal anti-inflammatory drugs (NSAIDs), have been under intensive examination [5].